Hypoxia Sensitive Metal β-Ketoiminate Complexes Showing Induced Single Strand DNA Breaks and Cancer Cell Death by Apoptosis by Lord, Rianne M et al.
University of Huddersfield Repository
Lord, Rianne M, Hebden, Andrew J, Pask, Christopher M, Henderson, Imogen R, Allison, Simon J., 
Shepherd, Samantha L, Phillips, Roger M and McGowan, Patrick C
Hypoxia Sensitive Metal -Ketoiminate Complexes Showing Induced Single Strand DNA Breaks β
and Cancer Cell Death by Apoptosis
Original Citation
Lord, Rianne M, Hebden, Andrew J, Pask, Christopher M, Henderson, Imogen R, Allison, Simon J., 
Shepherd, Samantha L, Phillips, Roger M and McGowan, Patrick C (2015) Hypoxia Sensitive Metal 
-Ketoiminate Complexes Showing Induced Single Strand DNA Breaks and Cancer Cell Death by β
Apoptosis. Journal of Medicinal Chemistry, 58 (12). pp. 4940-4953. ISSN 0022-2623 
This version is available at http://eprints.hud.ac.uk/24441/
The University Repository is a digital collection of the research output of the
University, available on Open Access. Copyright and Moral Rights for the items
on this site are retained by the individual author and/or other copyright owners.
Users may access full items free of charge; copies of full text items generally
can be reproduced, displayed or performed and given to third parties in any
format or medium for personal research or study, educational or not-for-profit
purposes without prior permission or charge, provided:
• The authors, title and full bibliographic details is credited in any copy;
• A hyperlink and/or URL is included for the original metadata page; and
• The content is not changed in any way.
For more information, including our policy and submission procedure, please
contact the Repository Team at: E.mailbox@hud.ac.uk.
http://eprints.hud.ac.uk/
Hypoxia Sensitive Metal β-Ketoiminato Complexes Showing Induced 
Single Strand DNA Breaks and Cancer Cell Death by Apoptosis 
Rianne M. Lord,a Andrew J. Hebden,a Christopher M. Pask,a Imogen R. Henderson,a Stephanie J. 
Lucas,a Simon J. Allison,b Samantha L. Shepherd,c Roger M. Phillips,c and Patrick C. McGowan.a* 
a School of Chemistry, University of Leeds, Leeds, UK, LS2 9JT. Email: p.c.mcgowan@leeds.ac.uk, Tel: +44(0)113 
3436404 
b Institute of Cancer Therapeutics, University of Bradford, Bradford, UK, BD7 1DP 
c Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, HD1 3DH 
 
ABSTRACT: A series of ruthenium and iridium complexes have been synthesised and characterised with 20 novel crystal 
structures discussed. The library of β-ketoiminato complexes has been shown to be active against MCF-7 (human breast 
carcinoma), HT-29 (human colon carcinoma), A2780 (human ovarian carcinoma) and A2780cis (cisplatin resistant human 
ovarian carcinoma) cell lines, with selected complexes being more than three times as active as cisplatin against the 
A2780cis cell line. Complexes have also been shown to be highly active under hypoxic conditions, with the activities of 
some complexes increasing with a decrease in O2 concentration. The enzyme thioredoxin reductase is over-expressed in 
cancer cells and complexes reported herein have the advantage of inhibiting this enzyme, with IC50 values measured in 
the nanomolar range. The anti-cancer activity of these complexes was further investigated to determine whether activity 
is due to effects on cellular growth or cell survival. The complexes were found to induce significant cancer cell death by 
apoptosis with levels induced correlating closely with activity in chemosensitivity studies. As a possible cause of cell 
death, the ability of the complexes to induce damage to cellular DNA was also assessed. The complexes failed to induce 
double strand DNA break or DNA crosslinking but induced significant levels of single DNA strand breaks indicating a 
different mechanism of action to cisplatin. 
Introduction 
Ruthenium has become one of the most popular metals 
used in drug development due to the metal’s easily 
accessible oxidation states, stability in air and the relative 
ease of synthesis of organometallic and coordination 
complexes. Most importantly ruthenium is thought to 
have slow in vivo ligand exchange and higher selectively 
towards cancer cells leading to lower toxicity.1-4 The 
discovery of organometallic ruthenium complexes first 
began with the library of [(η6-arene)Ru(II)(en)X]+ (X = 
halide, en = ethylenediamine) complexes synthesised by 
Sheldrick et al.5-7 The effect of the ligand was later 
explored by Sadler et al. substituting the neutral (N,N) 
ethylenediamine ligand for an anionic (O,O) β-diketonato 
ligand, showing a significant increase in cytoxicity of the 
complexes.8 In collaboration with Sadler, McGowan et al. 
first synthesised picolinamide Ru(II) and Os(II) arene 
complexes due to their relevence to previously reported 
metal ion-peptide chemistry9-11 and the possibility of 
different binding modes, through either a monoanionic 
(N,N) or a neutral (N,O) form. Studies showed that the 
more cytotoxic (N,N) complexes undergo rapid hydrolysis 
and bind preferentially to guanine, whereas switching the 
binding mode to (N,O) slows the rate of hydrolysis and 
switches off the activity.12,13 McGowan et al. also 
synthesised ruthenium and iridium complexes 
incorporating either a picolinamide (N,N), β-ketoiminato 
(N,O) or a naphthoquinone (O,O) ligand and compared 
the effects of these substitutions upon cytotoxicity. The 
IC50 values obtained for both HT-29 and MCF-7 cancer 
cell lines suggest that the binding mode is a critical 
determinant of complex activity. The lowest IC50 values 
were observed for the β-ketoiminato (N,O) complexes for 
both ruthenium and iridium and anti-cancer activity 
followed the general trend (N,O) > (O,O) > (N,N).14  
Herein we report the synthesis and characterisation of a 
new series of (N,O) and (O,O) complexes and analysis of 
their biological effects, gaining an understanding of their 
biological mechanisms. We report on the cytotoxic 
potential of our library of novel complexes, with potent 
cancer cell cytotoxicity observed, particular against the 
cisplatin resistant ovarian cell line (A2780cis). As many 
tumours have a significant hypoxic fraction and hypoxic 
tumour cells are typically resistant to standard 
chemotherapy and radiotherapy,15-17 IC50 values were also 
obtained for cells grown under low oxygen conditions. 
This enabled us to evaluate the potential of these 
complexes for targeting tumour cells that reside in a 
hypoxic microenvironment and which are a common 
cause of chemoresistance and tumour recurrence. Further 
 mechanistic studies have been undertaken to assess 
whether the anti-cancer activity of the novel complexes is 
due to effects upon cellular growth and proliferation or 
due to effects upon cell survival. The complexes were 
tested against HT-29 and A2780 cells at varying 
concentrations and effects on cell phenotype determined. 
Cell images were recorded under phase contrast 
microscopy at various time-points and levels of cell death 
by apoptosis and necrosis were quantified. Studies have 
also been carried out to assess the possibility of 
thioredoxin reductase (Trx-R) inhibition, using UVvis 
spectroscopy to monitor Trx-R activity following 
incubation of Trx-R enzyme with varying concentrations 
of our complexes. Finally, more detailed mechanistic 
studies have been carried out for possible damage to 
cellular DNA, given the ability of previous (N,N) 
complexes to bind guanine.12,13 The complexes have been 
assessed for double strand DNA breaks (DSB), DNA cross-
linking and single strand DNA breaks (SSB) using the 
Comet assay to quantify levels of different types of DNA 
damage in single cells, in order to gain structure activity 
relationships. 
Selective modifications were made within the library of 
complexes to gain an understanding of the characteristics 
needed for high in vitro cytotoxicity (Figure 1) with the 
following variables being assessed: 
removal of steric bulk, reducing the size of the ligand 
changing the binding mode of the ligand – (N,O) versus 
(O,O) 
changing the arene substituent - p-cymene or Cp* 
altering the metal centre - ruthenium versus iridium 
Figure 1 Modifications of the ‘piano stool’ complexes 
 
Results and discussion 
Synthesis and Characterisation 
The β-ketoenamine ligands L2-L13 were synthesised 
according to Scheme 1. Ligand L14 has previously been 
reported by Roshchupkina et al.18 The corresponding β-
diketonate ligands were prepared19 and dissolved with 
stirring in toluene, followed by addition of excess aniline 
and hydrochloric acid.20,21 Ligands were obtained as 
analytically pure compounds from solutions of hot 
ethanol in yields of 38-88% and characterised by 1H NMR 
spectroscopy, 13C{1H} NMR spectroscopy, mass 
spectrometry and microanalysis. Ligands L3-6, 8 and 11 
were also characterised by single crystal X-ray 
crystallography. 
The half-sandwich β-ketoiminato and β-diketonato 
complexes were synthesised according to Scheme 2. One 
equivalent of either [p-cymRuCl2]2 (Scheme 2a) or 
[Cp*IrCl2]2 (Scheme 2b) was stirred with two equivalents 
of the functionalised ligand and two equivalents of 
triethylamine in dichloromethane. Complexes 1-18 were 
isolated as analytically pure complexes from methanolic 
solutions in yields 46-71% and have been characterised by 
1H NMR spectroscopy, 13C{1H} NMR spectroscopy, mass 
spectrometry and microanalysis.14 Complexes 2, 4-14 and 
17-18 were also characterised by single crystal X-ray 
crystallography. 
 
Scheme 1 General synthetic route for the β-
ketoenamine ligands 
Scheme 2 General synthetic pathway for: a. Ru(II) 
complexes and b. Ir(III) complexes 
 
X-ray crystallographic data has been analysed for the 
novel β-ketominate ligands L3-6, 8 and 11, and single 
crystals were obtained by slow evaporation from hot 
ethanol. All angles around the central atoms are between 
118-125° (see Tables S1-2, SI), showing this section of the 
ligand is planar, with the atoms held together by an 
intramolecular hydrogen bonding interaction between N-
H…O (Figure 2) which is a feature in all crystal 
structures. 
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Figure 2 Molecular structures for ligands L3-6, 8 and 11. Hydrogen atoms omitted for clarity. Displacement ellipsoids 
are at the 50% probability level 
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Figure 3a Molecular structures for complexes 2 and 4-14. Hydrogen atoms omitted for clarity. Displacement ellipsoids 
are at the 50% probability level 
 
 X-ray crystallographic data has been analysed for 
complexes 2, 4-14, 17 and 18, and all single crystals were 
obtained using slow evaporation from a methanolic 
solution, appearing as orange/ red (ruthenium) or yellow 
(iridium) single crystals. Solutions were performed in a 
monoclinic Cc (4 and 7) or P21/c (14), triclinic P1 (2, 5, 6, 
8-13 and 17), or orthorhombic P212121 (18) space groups. All 
of the angles around the metal centre show the geometry 
expected for pseudo octahedral compounds which is 
common for half-sandwich “piano-stool” structures (see 
Tables S3-4, SI). The angles between the metal and 
bidentate ligands are in the range 83-90°, with the 
remaining three coordination sites occupied by the p-
cymene or Cp* ligand and the angles observed for their 
centroids to the chloride or bidentate ligand ranges 
between 124-133°. Molecular structures for complexes 2, 4-
14, 17 and 18 are shown in Figure 3a and 3b, with 
displacement ellipsoids placed at the 50% probability 
level and hydrogen atoms omitted for clarity. 
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Figure 3b Molecular structures for iridum(III) 
complexes 17 and 18. Hydrogen atoms omitted for 
clarity. Displacement ellipsoids are at the 50% 
probability level 
 
 
a) p-cym…Cg 
interaction in 
complex 1 
b) p-cym…Cg and p-
cym…Cl interac-
tion for complex 2 
 
c) p-cym…Cl interaction in complex 8 
Figure 4 Intramolecular interactions for a) complex 1, b) 
complex 2 and c) complex 8 
The 1H NMR spectra for the ruthenium β-ketoiminato 
complexes show a significant upfield shift of 1.3-1.6 ppm 
for one of the p-cymene hydrogens. Analysis of the X-ray 
structure shows one of these hydrogens undergoes 
intramolecular T-stacking interactions with the aniline 
ring at D…A distances between 3.33-3.62 Å (Figure 4). 
This type of interaction has previously been reported with 
a library of complexes of the type [areneRuCl(XY)] (where 
XY = N,O ligand) synthesised by Dyson et al., in which it 
was noted these complexes can exist as two conformers, 
with variable temperature NMR studies showing the 
presence of both conformers at lower temperatures.22 
Interactions are also seen between the p-cymene 
hydrogen and the ancillary chloride ligand with D...A 
distances of 3.37-3.34Å (Figure 4). 
 
Cell Line Chemosensitivity Studies 
In order to gain information about the structure-
activity relationships of the different complexes, 
chemosensitivity studies were performed and IC50 values 
were determined for HT-29, MCF-7, A2780 and A2780cis 
cancer cell lines exposed to each of complexes 1-18 or to 
cisplatin (Table 1 and Figure S2). The results show that 
the ruthenium β-ketoiminato complexes are all cytotoxic 
towards the cancer cell lines tested, with particular 
activity against both A2780 and A2780cis cell lines. 
Complex 1 was the most active complex against all four 
cancer cell lines, with the lowest IC50 value for MCF-7 of 
1.9 ± 0.1 µM (cisplatin 0.98 ± 0.09 µM), and significant 
activity against the cisplatin-resistance cell line A2780cis 
in which it was ~3-fold more active than cisplatin (3.13 ± 
0.09 µM versus 10.5 ± 0.2 µM). This suggests that the 
mechanism of action and resistance of these complexes is 
different from cisplatin and raises the possibility that 
some of these complexes could potentially be used to 
treat cancer which has become resistant to cisplatin. This 
library shows that complexes 1-7,which have  electron 
withdrawing substituents, are the most potent against all 
tested cell lines. While introduction of electron donating 
groups or sterically bulky groups usually leads to a slight 
decrease in activity (complexes 11, 12, 14, 16 and 17). 
However, on comparison of substituents in the para 
position, when a methyl substituent was introduced 
(complex 11), anti-cancer activity increased in comparison 
to the para electron withdrawing substituents and this 
complex was the most active para complex against MCF-7 
cells, with an IC50 value of 2.1 ± 0.1 µM (cisplatin 1.07 ± 
0.10 µM). Control experiments were also performed to 
investigate whether the ligands alone possess any 
cytotoxic activity in vitro. Ligands L2-4 and L7 were tested 
against HT-29 cancer cells and all were considered to be 
inactive with IC50 values greater than the tested threshold 
(>250 µM) (Table 1) 
 
 Table 1 IC50 values for cisplatin and complexes 1-18 against HT-29, MCF-7, A2780, A2780cis and ARPE-19 cell lines. 
The values in parenthesis represent the IC50 values for the ARPE-19 cells divided by IC50 values for individual 
cancer cells (values greater than 1 indicate selectivity for cancer cells over the non-cancer ARPE-19 cells). 
Complex 
HT-29 
IC50 (µM) ± SD MCF-7 IC50 (µM) ± SD A2780 IC50 (µM) ± SD A2780cis IC50 (µM) ± SD ARPE-19 IC50 (µM) ± SD 
Cisplatin 2.40 ± 0.10 (2.49) 1.09 ± 0.08 (5.47) 0.94 ± 0.04 (6.35) 10.50 ± 0.20 (0.57) 5.97 ± 0.95 
1 3.50 ± 0.30 (1.28) 1.90 ± 0.10 (2.36) 2.60 ± 0.08 (1.72) 3.13 ± 0.09 (1.43) 4.48 ± 0.07 
2 10.50 ± 0.40 5.07 ± 0.09 2.80 ± 0.10 3.47 ± 0.07 - 
3 5.40 ± 0.09 3.00 ± 0.20 1.70 ± 0.10 3.80 ± 0.10 - 
4 4.30 ± 0.50 3.22 ± 0.09 2.35 ± 0.04 5.59 ± 0.05 - 
5 11.40 ± 0.60 3.50 ± 0.20 2.50 ± 0.10 6.40 ± 0.10 - 
6 12.60 ± 0.02 3.27 ± 0.08 2.86 ± 0.04 11.50 ± 0.30 - 
7 6.10 ± 0.30 (1.27) 3.55 ± 0.09 (2.18) 2.5 ± 0.2 (3.10) 3.69 ± 0.09 (2.10) 7.76 ± 0.07 
8 10.30 ± 0.60 (1.48) 6.20 ± 0.20 (2.47) 2.3 ± 0.2 (6.67) 7.00 ± 0.04 (2.19) 15.33 ± 0.41 
9 11.80 ± 0.80 (1.02) - - - 12.00 ± 1.47 
10 12.80 ± 0.50 - - - - 
11 10.21 ± 0.09 (0.89) 2.9 0 ± 0.10 (3.16) 2.87 ± 0.05 (3.19) 9.1 ± 0.1 (1.01) 9.17 ± 2.36 
12 22.00 ± 2.00 (0.32) 13.00 ± 0.20 (0.55) - - 7.17 ± 0.93 
13 6.30 ± 0.30 (0.57) 7.20 ± 0.20 (0.50) 1.90 ± 0.10 (1.91) 3.80 ± 0.09 (0.95) 3.62 ± 0.03 
14 53.00 ± 1.00 (0.60) - 56.00 ± 2.00 (0.57) - 32.03 ± 9.23 
15 18.00 ± 2.00 (2.86) 18.40 ± 0.80 (2.80) 19.40 ± 0.80 (2.66) 24.30 ± 0.50 (2.12) 51.55 ± 5.14 
16 5.10 ± 0.30 3.40 ± 0.20 5.70 ± 0.10 5.80 ± 0.50 - 
17 83.00 ± 3.00 - - - - 
18 93.00 ± 7 .00 (>1) 51.00 ± 4.00 (>2) 35.00 ± 1.00 (>2.9) 51.00 ± 1.00 (>2) >100 
L2 > 250 - - - - 
L3 > 250 - - - - 
L4 > 250 - - - - 
L7 > 250 - - - - 
 
Selectivity for cancer cells 
Comparing the response of tumour cell lines to non-
cancer ARPE-19 cells provides a preliminary indication of 
selectivity. Whilst compounds 9, 12, 13 and 14 show no 
selectivity towards cancer cells (ratio of IC50 values in 
AREP-19 cells to cancer cells ≤ 1), compounds 1, 7, 8, 11 
and 15 showed evidence of selectivity to certain cancer 
cells (Table 1). The magnitude of the selectivity observed 
in the test compound series was comparable to that 
obtained for cisplatin with ratio’s of IC50 values in ARPE-
19 to cancer cells ranging from 6.67 to 1.27 for test 
compounds and 6.35 to 0.57 for cisplatin (Table 1). 
Compound 8 in particular demonstrated good selectivity 
against all the cancer cell lines  tested with  selectivity 
ranging from 6.67 to 1.48 fold increased chemosensitivity 
towards cancer cells  compared to  ARPE-19 non-cancer 
cells (A2780: 6.67; A2780cis: 2.19; MCF7: 2.47; HT29: 
1.48; Table 1).These results provide a preliminary 
indication that some compounds are selectively toxic to 
cancer cells.  
Due to the high in vitro activity for complex 1, 
complexes 15, 16 and 18 were synthesised in order to make 
comparisons between the biological mechanisms on 
changing both the ligands and metal centres. Complexes 1 
and 16 incorporate a 3-fluoro-β-ketoiminato (N,O) ligand, 
whilst complex 15 and 18 incorporate the 3-fluoro-β-
diketonato (O,O) ligand, on ruthenium and iridium 
respectively. On comparison of complex 1 (N,O) and the β-diketonato complex 15 (O,O), changing the binding 
mode and hence elimination of the aniline ring, 
dramatically decreased cell line cytotoxicity, with 
complex 15 being up to 9-fold less active than its (N,O) 
analogue. Also on comparison of two (N,O) complexes 1 
and 14, substituting the aniline ring for NH (14) showed a 
21-fold decrease in activity when compared to 1. The 
iridium Cp* β-ketoiminato complex 16 was synthesised 
and compared to the iridium β-diketonato analogue 18. 
As seen with the ruthenium complexes, the (O,O) ligand 
had up to an 18-fold decrease in activity against HT-29. 
Again on comparison of two (N,O) complexes 16 and 17, 
the aniline was substituted for NH (17) and the activity 
decreased by 16-fold when compared to complex 16. 
 These results indicate that for the complexes tested, the 
aniline ring is critical for high in vitro anti-cancer activity 
and on elimination of this ring complex activity is 
substantially diminished, proving that the design of the 
ligand is essential in drug development. 
Influence of Hypoxia 
For many solid tumours, a significant proportion of the 
tumour cells are under conditions of limiting oxygen or 
hypoxia and the cellular environment is reducing. The 
hypoxia-inducible factor-1 (HIF-1) is central to the cell’s 
response to hypoxia and under hypoxic conditions it 
activates a transcriptional program that helps tumour cell 
adaptation and survival under low oxygen conditions.23-27 
Transition metals have the potential to be reduced under 
hypoxic conditions and these changes in oxidation states 
could lead to changes in structure, binding mode, cellular 
drug uptake and metabolism as well cellular mechanism 
of action and the effectiveness of this. Using complexes 1, 
15, 16 and 18, 5-day in vitro MTT studies were conducted 
under hypoxic conditions at both 0.1% and 1.0% O2 
against HT-29 cells, in order to assess the impact of 
oxygen concentration upon chemosensitivity (Figure 5). 
The complexes were compared to the hypoxia-activated 
pro-drug tirapazamine and to cisplatin.28 Results show 
that reducing the O2 concentration gave a general 
decrease in cytotoxicity for the (O,O) complexes 15 and 
18, with the reduction in activity more pronounced at 
0.1% O2. The iridium (N,O) complex 16 is active under 
hypoxic conditions albeit less so than under normoxia 
(21% O2), with an IC50 value of 20 ± 2 µM at 0.1% O2. 
Complex 1 shows a small decrease in its activity in 
response to low oxygen conditions, but remains highly 
active even at 0.1% O2 concentration, confirming its 
potential as a drug candidate for targeting both normoxic 
and hypoxic cancer cells.  
Figure 5 Hypoxic values for complexes 1, 15, 16 and 18 
against HT-29 
The preliminary in vitro screening of the complexes 
indicated that the complexes with a substituents in the 
para position of the β-ketoiminato ligand were highly 
potent against the cell lines tested (Table 1), and these 
complexes made good candidates for hypoxia studies. 
Therefore, in order to further probe the effects of hypoxia 
on these complexes a range of para substituted complexes 
(2, 3, 8, 9 and 11) were tested under hypoxic conditions 
(Figure 6). Complexes tested at 0.1% O2 were still active 
under hypoxic conditions and for all para complexes 
tested, the anti-cancer activity actually increased at 0.1% 
O2, indicating that these complexes are hypoxia sensitive. 
The most noticeable results were seen for complexes 2 
and 8, which both have nearly 2-fold lower IC50 values 
under hypoxic conditions. This indicates the potential of 
these complexes or similar derivatives as hypoxia 
targeting anti-cancer agents. 
 
Figure 6 Hypoxic results for complexes 2, 3, 8, 9 and 11 
against HT-29 
Inhibition of thioredoxin reductase activity 
The MTT assay is the gold standard for in vitro 
chemosensitivity studies and IC50 determination but it 
does not provide any information as to how the drugs 
may possess their anti-cancer effects. To try and gain 
some preliminary insight into this, additional assays were 
conducted for possible effects of the drugs upon, a) 
thioredoxin reductase activity, b) induction of DNA 
damage, and, c) induction of cell death. The biological 
effects of the thioredoxin reductase 1 (Trx-R) system have 
been shown to contribute to tumour growth and 
progression.29 Over-expression of thioredoxin reductase 1 
has been reported in several tumour types and the 
enzyme is an important therapeutic target in anti-cancer 
drug development.30-32 In order to investigate the mode of 
action of our novel complexes, the inhibition of Trx-R 
activity by complexes 1, 15, 16 and 18 was investigated. 
Previously, a range of iridium picolinamide complexes 
were found to inhibit Trx-R, with IC50 values in the 
nanomolar range. However, the analogous ruthenium 
picolinamide complexes failed to show any enzyme 
inhibition.33 In this work, both ruthenium and iridium β-
ketoiminato complexes (1 and 16) were found to be potent 
Trx-R inhibitors with IC50 values in the nanomolar range. 
The β-diketonato complexes 15 and 18 are less active 
against Trx-R, but still have IC50 values in the low 
micromolar range (see Figure S3). Trx-R inhibition may 
thus contribute to the anti-cancer activity of some of our 
novel complexes; although it is likely that other 
mechanisms may also be important. 
Induction of cancer cell death by apoptosis 
The IC50 values determined by chemosensitivity studies 
using the MTT assay indicate the concentration of drug 
required for a 50% reduction in viable cell number. 
Whilst this provides invaluable information on the 
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 activity of the drug against the cell line testing, the MTT 
assay does not distinguish between effects on cell 
proliferation and effects on cell survival. Thus, the 
observed activity of our novel complexes towards the four 
cancer cell lines could be caused by induction of cell 
growth arrest or the complexes may actually cause cell 
death. Cell images under phase contrast microscopy at 
various time-points after complex addition suggested 
induction of cell death rather than growth arrest. Using 
flow cytometry and annexin V/propidium iodide staining 
the percentage of live cells, early apoptotic cells and late 
apoptotic/necrotic cells were quantified following 
incubation of HT-29 or A2780 cells with 10 or 20µM of 
complexes 1, 15, 16 and 18 for 48 hours (Figure 7 and 
Table S8). 
The β-ketoiminato complexes 1 and 16, which were 
amongst the most active complexes in the MTT 
chemosensitivity studies, induced significant levels of 
apoptotic cell death in both the HT29 (Figure 7a) and 
A2780 (Figure 7b) cancer cell lines in a dose-responsive 
manner. A 48 hour exposure of HT29 cells to 10 µM of the β-ketominate ruthenium complex 1 resulted in ~50% early 
apoptotic cells and ~40% late apoptotic/necrotic cells. A 
20 µM dose resulted in over 70% of cells staining positive 
for late apoptosis/necrosis. 20 µM of the active β- 
ketoiminato iridium complex 16 also induced significant 
apoptosis, with 31.7% early apoptotic cells and 49.9% late 
apoptotic or necrotic cells following 48 hour exposure. In 
contrast, the ruthenium and iridium β−diketonato 
analogues 15 and 18 respectively, induced only very low 
levels of apoptosis/necrosis, consistent with their much 
higher IC50 values and lower activity in the 
chemosensitivity studies (see Table 1). Although levels of 
apoptosis and necrosis were higher than background 
levels obtained with the controls and higher levels were 
induced by 20 µM of drug than with 10 µM, even at the 
highest drug concentration of 20 µM the majority of cells 
(>84%) were still viable. These observations indicate a 
clear correlation between IC50 value and levels of 
apoptosis/necrosis induced. 
A very similar pattern was also observed for A2780 cells 
demonstrating that for these two cancer cell lines at least, 
the ruthenium and iridium β-ketoiminato complexes 1 
and 16 induce high levels of cancer cell death by 
apoptosis, in a dose-dependent manner. This is consistent 
with their low IC50 values and indicates a mechanism by 
which they are able to exert their in vitro anti-cancer 
activity which merits further future investigation. 
 
Analysis of cellular DNA damage by the comet assay 
Accumulation of cellular DNA damage ultimately leads 
to the demise of the cell by apoptosis (programmed cell 
death). As a potential cause of the apoptotic phenotype 
induced by complexes 1 and 16 (see Figure 7) we 
therefore determined whether the complexes induce any 
form of cellular DNA damage. Complexes 1, 15, 16, and 18 
and cisplatin were tested for induction of double strand 
DNA breakage (DSB), single strand DNA breakage (SSB) 
and DNA cross-linking. Increasing concentrations of the 
complexes or of cisplatin were incubated with HT-29 cells 
for 24 hours before harvesting and quantification of the 
levels of different types of DNA damage in single cells 
using the either the alkaline or neutral comet assay (see 
SI). None of the complexes induced significant levels of 
double strand DNA breaks at any of the concentrations 
tested (Figure 8a) and this was also the case for cisplatin, 
as previously reported.34,35 
a) Apoptosis results for complexes 1, 15, 16 and 18 
against HT-29 
 
b) Apoptosis results for complexes 1, 15, 16 and 18 
against A2780 
Figure 7 Apoptosis results for complexes 1, 15, 16 and 
18 against HT-29 and A2780 
The complexes also failed to induce DNA cross-linking 
(see Figure S4-S6), whereas cisplatin induced significant 
DNA cross-linking, consistent with its mechanism of 
action.36 Importantly however, the ruthenium β-
ketoiminato (N,O) complex 1 induced high levels of 
single-strand DNA breaks with levels of SSB damage 
increasing in a dose-dependent manner with increasing 
concentrations of complex 1 (Figure 8b). In contrast the 
analogous ruthenium β-diketonato (O,O) complex 15 
caused no single strand DNA breakage (Figure 9) 
indicating the importance of the binding ligand and 
consistent with the much lower activity of complex 15 
compared to complex 1 in both chemosensitivity studies 
(Table 1) and cell viability analyses (Figure 7). 
  
 
Double Strand Breakage (DSB) 
 
Single strand Breakage (SSB) 
Figure 8 DSB and SSB results for complexes 1, 15, 16 
and 18 against HT-29 
 
The iridium complexes showed the same general trend, 
with the β-ketoiminato (N,O) complex 16 also inducing 
SSB formation similar to its ruthenium analogue 
(complex 1) although the extent of DNA damage was less. 
The iridium β-diketonato (O,O) complex 18, like its 
ruthenium β-diketonato counterpart (complex 15), 
induced no SSB formation. Thus, for both ruthenium and 
iridium complexes, the (N,O) ligand appears to be 
important for complex induction of cellular single strand 
DNA breaks. Whilst other mechanisms may also be 
involved, the induction of SSB damage provides a possible 
cause of the apoptotic phenotype induced by complexes 1 
and 16.  
The observation that complexes 1 and 16 induce signifi-
cant single strand DNA breaks in a dose-dependent man-
ner but few double strand breaks or DNA cross-links 
(Figures 8, 9 and Figures S4-S6) suggests a different 
mechanism of action to cisplatin which primarily induces 
DNA cross-linking. It is also informative with respect to 
possible combinational chemotherapeutic approaches, 
suggesting that complexes 1 and 16 may be particularly 
effective if used in combination with inhibitors of single 
strand break repair, such as PARP inhibitors. Another 
approach that may be effective is in combination with 
DNA damaging chemotherapeutic agents that work by a 
different mechanism, for example by inducing DSBs, such 
as doxorubicin or etoposide. Future studies will investi-
gate how the compounds might induce SSBs, for example 
by inhibition of topoisomerase I, and will include combi-
natorial studies with other classes of DNA damaging 
chemotherapeutic agents for synergistic effects.  
Overall, our results identify the ruthenium and iridium 
complexes with the β-ketoiminato (N,O) ligand 
(complexes 1 and 16) as the most potent and promising of 
the novel complexes and these are good candidates for 
future investigation including more detailed mechanistic 
studies, in vitro and in vivo ADME studies and analysis of 
cancer selectivity in vivo. 
 
SSB for Cisplatin 
 
SSB fo Complex 1 
 
SSB for Complex 15 
Figure 9 Bar-charts to tail moment (extent of dam-
age) versus concentration for the SSB assay for a) 
Cisplatin; b) Complex 1 and c) Complex 15 
 
Conclusions  
From the library of novel ruthenium and iridium 
complexes tested in this study, our results identify the 
complexes with a β-ketoiminato ligand as the most active. 
IC50 values varied depending on the complex and cell line 
 but were typically below 15 µM for all four cancer cell 
lines tested (HT-29, MCF-7, A2780, A2780cis). 
Importantly, almost all of the β-ketoiminato complexes 
were slightly more active than cisplatin against the 
cisplatin-resistant cell line A2780cis. Wth complex 1 
showing a 3-fold increase in activity when compared to 
cisplatin. Complexes with the aniline ring removed were 
tested and results showed this feature to also be essential 
for potent in vitro anti-cancer activity. A selection of 
complexes were tested under hypoxic (1% O2) or severely 
hypoxic (0.1% O2) conditions against HT-29 cells, and 
interestingly whereas the β-diketonato complexes tested 
were significantly less active under hypoxia, many of the β-ketoiminato complexes were more active under hypoxia 
indicating that these β-ketoiminato complexes are 
hypoxia-sensitive. As a possible mechanism of action we 
investigated the inhibition of thioredoxin reductase, with 
results showing inhibition of this enzyme, with IC50 values 
in the nanomolar range. Further mechanistic 
investigation showed that the β-ketoiminato complexes 
fail to induce growth arrest but i) induce significant 
cancer cell death by apoptosis and, ii) single strand DNA 
breakage - indicating a different mechanism of action to 
cisplatin. The selective modifications made to the core 
‘piano-stool’ complex in this study and our initial 
downstream analyses of the biological effects of this (eg 
on IC50, cell viability, DNA damage induction) highlight 
the importance of the size and binding mode of the ligand 
for activity. The unexpected enhanced activity of many of 
the β-ketoiminato complexes under hypoxic conditions 
warrants further investigation but is encouraging in the 
search for novel anti-cancer agents that are capable of 
targeting both normoxic and hypoxic cells of a solid 
tumour. 
 
Experimental 
Materials 
All chemicals were supplied by Sigma-Aldrich Chemical Co., 
Acros Organics, Strem Chemical Co. and BOC gases. 
Functionalised β-diketonate and β-ketoiminate ligands were 
prepared by adaptations of literature methods.19,20 
Deuterated NMR solvents were supplied by Sigma-Aldrich 
Chemical Co. or Acros Organics. 
 
Analysis 
All NMR spectra were recorded by either the author or Mr 
Simon Barrett on a Bruker DPX 300 or a Bruker DPX 500 
spectrometer. Microanalyses were recorded by Mr. Ian 
Blakeley or Ms Tanya Marinko-Covell at the University of 
Leeds Microanalytical Service. Mass Spectra were recorded 
by either Ms. Tanya Marinko-Covell or the author, on a 
Micromass ZMD spectrometer with electrospray ionisation 
and photoiodide array analyser at the University of Leeds 
Mass Spectrometry Service. 
 
Elemental Analysis 
All biologically evaluated compounds must demonstrate a 
purity >95%, and therefore the compounds synthesised 
within this report have been analysed using elemental (CHN) 
analysis, by means of combustion. This technique requires 
the sample to be burned in an excess of oxygen and has a 
variety of traps which collect the combustion products: CO2, 
H2O and NO. These masses are then used to help calculated 
the masses of the ‘unknown’ product. The experimental 
values are compared with the calculated values of the 
sample, and all synthesised compounds herein are within 
0.5% of the calculated values.  
 
X-ray Crystallography 
A suitable single crystal was selected and immersed in an 
inert oil. The crystal was then mounted on a glass capillary or 
nylon loop and attached to a goniometer head on a Bruker 
X8 Apex diffractometer using graphite monochromated Mo-
Kα radiation (λ = 0.71073 Å) or an Agilent SuperNova 
diffractometer using mirror monochromated Mo-Kα 
radiation (λ = 0.71073 Å), using 1.0° φ-rotation frames. The 
crystal was cooled to between 100-173 K by an Oxford 
Cryostream low temperature device.37 The full data sets were 
recorded and the images processed using DENZO and 
SCALEPACK programs38 or CrysAlis Pro software.39  
 
Structure solution by direct methods was achieved through 
the use of SHELXS programs,40 and the structural model 
refined by full matrix least squares on F2 using SHELX97 
Unless otherwise stated, hydrogen atoms were placed using 
idealised geometric positions (with free rotation for methyl 
groups), allowed to move in a “riding model” along with the 
atoms to which they were attached, and refined isotropically. 
Molecular graphics were plotted using POV-Ray41 via the 
XSeed program40 and OLEX2.42 Editing of CIFs and 
construction of tables of bond lengths and angles were 
achieved using WC43 and PLATON.44 
 
Synthesis 
Ligands L2-L12  
All ligands were synthesised by dissolving the corresponding 
functionalised β-diketonate (0.5 g) in toluene (10 mL), 
followed by addition of aniline (1 mL) and HCl (0.5 mL). The 
mixture was stirred overnight and the precipitate filtered 
under reduced pressure. The solvent was removed from the 
filtrate and then recrystallised from hot ethanol to yield 
analytically pure compounds. 
 
Ligand L2 (0.63 g, 2.5 mmol, 87%) 
1H NMR (CDCl3, 300 MHz, 300 K) δ 13.05 (s, 1H, NH), 7.94 (v. 
dd, 2H, CH, 3J(1H-1H) = 9.2 Hz and 3J(1H-19F) = 2.3 Hz), 7.39 
(br. t, 2H, CH, 3J(1H-1H) = 7.9 Hz), 7.24 (br. t, 1H, CH, 3J(1H-
1H) = 7.6 Hz), 7.19 (br. d, 2H, CH, 3J(1H-1H) = 7.2 Hz), 7.11 (v. t, 
2H, CH, 3J(1H-1H) = 8.7 Hz and 4J(1H-19F) = 1.9 Hz), 5.85 (s, 1H, 
methine CH, H9), 2.15 (s, 1H, aliphatic CH3) 
13C{1H} NMR 
(CDCl3, 75MHz, 300K) δ 187.2 (Q), 164.5 (d, Q C-F, 1J(13C-19F) 
= 249.7 Hz), 162.4 (Q), 138.5 (Q), 129.3 (d, 2 x CH, 2J(13C-19F) = 
8.7 Hz), 129.2 (2 x CH), 125.9 (CH), 124.8 (2 x CH), 115.2 (d, 2 x 
CH, 3J(13C-19F) = 21.0 Hz), 93.8 (methine CH), 20.4 (aliphatic 
CH3) Analysis Calculated for C16H14FNO: C 74.30 H 5.53, N 
5.49% Analysis Found for C16H14FNO: C 74.35, H 5.40, N 
5.25% ES MS (+): m/z 255.6 [M+] 
 
Ligand L3 (0.35 g, 1.0 mmol, 51%) 
1H NMR (CDCl3, 300 MHz, 300 K) δ 13.12 (s, 1H, NH), 7.90 (d, 
2H, CH, 3J(1H-1H) = 8.5 Hz), 7.44 (d, 2H, CH, 3J(1H-1H) = 8.5 
 Hz), 7.42 (m, 1H, CH), 7.25 (d, 2H, CH, 3J(1H-1H) = 7.5 Hz), 
7.22 (m, 2H, CH, 3J(1H-1H) = 8.5 Hz), 5.89 (s, 1H, methine 
CH), 2.19 (s, 3H, aliphatic CH3) 
13C{1H} NMR (CDCl3, 75MHz, 
300K) δ 163.1 (Q), 137.4 (Q), 129.6 (CH), 128.9 (CH), 126.4 
(CH), 125.3 (CH), 98.4 (methine CH), 20.8 (aliphatic CH3) 
Analysis Calculated for C16H14ClNO: C 70.70 H 5.19, N 5.20, Cl 
13.10% Analysis Found for C16H14ClNO: C 70.70, H 5.25, N 
5.40, Cl 12.80% ES MS (+): m/z 272.0 [MH+] 
 
Ligand L4 (0.58 g, 2.0 mmol, 88%) 
1H NMR (CDCl3, 300 MHz, 300 K) δ 12.86 (s, 1H, NH), 7.51 (d, 
1H, CH, 3J(1H-1H) = 8.4 Hz), 7.46 (d, 2H, CH), 7.42 (d, 1H, CH, 
3
J(1H-1H) = 7.8 Hz), 7.33-7.30 (m, 3H, CH), 7.24 (d, 2H, CH, 
3
J(1H-1H) = 8.7 Hz), 5.89 (s, 1H, methine CH), 2.14 (s, 3H, 
aliphatic CH3) 
13C{1H} NMR (CDCl3, 75MHz, 300K) δ 188.7 
(Q), 163.3 (Q), 139.9 (Q), 138.6 (Q), 135.7 (Q), 132.2 (Q), 130.7 
(CH), 130.4 (CH), 129.7 (2 x CH), 127.4 (CH), 126.7 (CH), 125.4 
(2 x CH), 98.5 (methine CH), 20.6 (aliphatic CH3) Analysis 
Calculated for C16H13Cl2NO: C 62.809 H 4.28, N 4.60, Cl 
23.20% Analysis Found for C16H13Cl2NO: C 62.70, H 4.25, N 
4.50, Cl 22.0% ES MS (+): m/z 306.1 [MH+] 
 
Ligand L5 (0.46 g, 2.2 mmol, 68%) 
H NMR (CDCl3, 300 MHz, 300 K) δ 12.71 (s, 1H, NH), 7.43 (m, 
1H, CH), 7.33 (br. t, 2H, CH, 3J(1H-1H) =7.5 Hz), 7.24 (br. s, 1H, 
CH), 7.21-7.16 (m, 2H, CH), 7.13(d, 2H, CH, 3J(1H-1H) = 7.5 
Hz), 5.43 (s, 1H, methine CH), 2.03 (s, 3H, aliphatic CH3) 
13C{1H} NMR (CDCl3, 75 MHz, 300 K) δ 187.8 (Q), 163.2 (Q), 
142.4 (Q), 138.1 (Q), 132.6 (Q C-Cl), 131.3 (CH), 130.0 (CH), 
129.3 (CH), 126.4 (CH), 125.1 (CH), 97.9 (methine CH), 20.2 
(aliphatic CH3) Analysis Calculated for C16H13Cl2NO: C 62.67, 
H 4.29, N 4.58, Cl 23.15% Analysis Found for C16H13Cl2NO: C 
62.65, H 4.20, N 4.45, Cl 23.30 ES MS (+): m/z 306.2 [M+] 
 
Ligand L6 (0.10 g, 0.29 mmol, 55%) 
1H NMR (CDCl3, 500.23 MHz, 300.1 K) δ 12.75 (br. s, 1H, NH), 
7.43-7.39 (m, 3H, 3 x CH), 7.33 (d, 1H, CH, 3J (1H-1H) = 8.2 
Hz), 7.29 (br. d, 1H, CH, 3J (1H-1H) = 7.3 Hz), 7.22 (br. d, 2H, 
CH, 3J (1H-1H) = 7.6 Hz), 5.45 (s, 1H, methine CH), 2.11 (s, 3H, 
aliphatic CH3) 
13C{1H} NMR (CDCl3, 125.9 MHz, 300.0 K) δ 
187.9 (Q), 163.4 (Q), 141.6 (Q), 138.0 (Q), 134.5 (Q C-Cl), 132.4 
(Q C-Cl), 131.0 (Q C-Cl). 129.3 (CH), 128.4 (CH), 126.9 (CH), 
126.4 (CH), 125.1 (CH), 97.8 (methane CH), 20.2 (CH3) 
Analysis Calculated for C16H12Cl3NO: C 56.42, H 3.55, Cl 31.22, 
N 4.11% Analysis Found for C16H12Cl3NO: C 56.25, H 3.45, Cl 
31.05, N 4.05% ES MS (+): m/z 340.0 [M+] 
 
Ligand L7 (0.42 g, 1.3 mmol, 62%) 
1H NMR (CDCl3, 300 MHz, 300 K) δ 13.08 (s, 1H, NH), 8.06 (t, 
1H, CH, 4J (1H-1H) = 1.7 Hz), 7.84 (br. dt, 1H, CH, 3J (1H-1H) = 
8.0 Hz and 3J (1H-1H) = 1.5 Hz), 7.59 (dq, 1H, CH, 3J (1H-1H) = 
7.9 Hz and 4J (1H-1H) = 0.9(x3) Hz), 7.40 (br. t, 2H, CH, 3J(1H-
1H) = 8.1 Hz) 7.31 (t, 1H, CH, 3J (1H-1H) = 7.9 Hz), 7.25 (br. t, 
1H, CH, 3J (1H-1H) = 7.2 Hz), 7.20 (br. d, 2H, CH, 3J (1H-1H) = 
7.5 Hz), 5.83 (s, 1H, methine CH), 2.16 (s, 3H, aliphatic CH3) 
13C{1H} NMR (CDCl3, 75 MHz, 300 K) δ 186.7(Q), 163.0 (Q), 
142.0 (2 x Q), 138.4 (Q C-Br), 133.6 (CH), 130.2 (CH), 129.8 
(CH), 129.2 (CH), 126.1 (CH), 125.6 (CH), 124.9 (CH), 94.0 
(methine CH), 20.4 (aliphatic CH3) Analysis Calculated for 
C16H14BrNO: C 60.76, H 4.47, N 4.43% Analysis Found for 
C16H14BrNO: C 60.80, H 4.45, N 4.43% ES MS (+): m/z 316.3 
[M+] 
 
Ligand L8 (0.44 g, 1.0 mmol, 67%) 
1H NMR (CDCl3, 300 MHz, 300 K) δ 12.42 (s, 1H, NH), 7.73 (d, 
2H, CH, 3J(1H-1H) = 7.2 Hz), 7.56 (m, 1H, CH), 7.45 (d, 2H, 
CH), 7.42 (d, 1H, CH, 3J(1H-1H) = 7.5 Hz) 7.37 (d, 2H, CH, 
3
J(1H-1H) = 8.0 Hz), 5.87 (s, 1H, methine CH), 2.19 (s, 3H, 
aliphatic CH3) 
13C{1H} NMR (CDCl3, 75 MHz, 300 K) δ 173.9 
(Q), 134.9 (Q), 131.9 (2 x CH), 130.4 (2 x CH), 129.9 (2 x CH), 
126.8 (CH), 125.0 (2 x CH), 102.2 (methane CH), 22.1 (aliphatic 
CH3) Analysis Calculated for C16H14BrNO: C 60.80, H 4.46, N 
4.40% Analysis Found for C16H14BrNO: C 61.10, H 5.05, N 
4.40% ES MS (+): m/z 316.0 [MH+] 
 
Ligand L9 (0.76 g, 2.1 mmol, 76%) 
1H NMR (CDCl3, 500.23 MHz, 300.1 K) δ 13.09 (br. s, 1H, NH), 
7.79 (d, 2H, CH, 3J (1H-1H) = 8.3 Hz), 7.65 (d, 2H, CH, 3J (1H-
1H) = 8.3 Hz), 7.39 (br. t, 2H, CH, 3J (1H-1H) = 7.8 Hz), 7.25 
(br. t, 1H, CH, 3J (1H-1H) = 7.3 Hz), 7.19 (br. d, 2H, CH, 3J (1H-
1H) = 7.3 Hz), 5.84 (s, 1H, methine CH), 2.15 (s, 3H, aliphatic 
CH3) 
13C{1H} NMR (CDCl3, 75 MHz, 300 K) δ 187.4 (Q), 162.8 
(Q), 139.4 (2 x Q), 138.4 (Q C-I), 137.5 (2 x CH), 129.2 (2 x CH), 
128.7 (2 x CH), 126.0 (CH), 124.9 (2 x CH), 93.8 (methine CH), 
20.4 (aliphatic CH3) Analysis Calculated for C16H14INO: C 
52.91, H 3.89, I 34.94, N 3.86% Analysis Found for C16H14INO: 
C 52.95, H 4.10, I 34.65, N 3.75% ES MS (+): m/z 364.0 [MH+] 
 
Ligand L10 (0.40 g, 1.4 mmol, 38%) 
1H NMR (CDCl3, 500.13 MHz, 319.2 K) δ 13.01 (br. s, 1H, NH), 
7.91 (br. d, 2H, CH, 3J (1H-1H) = 8.8 Hz), 7.39-7.34 (br. t, 2H, 
CH, 3J (1H-1H) = 7.3 Hz), 7.23-7.20 (m, 1H, CH), 7.18 (br. d, 2H, 
CH, 3J (1H-1H) = 8.8 Hz), 5.86 (s, 1H, methine CH), 4.11 (q, 2H, 
ethoxy CH2, 
3
J (1H-1H) = 6.7 Hz ), 2.14 (s, 3H, aliphatic CH3), 
1.45 (t, 3H, ethoxy CH3, 
3
J (1H-1H) = 6.7 Hz) 13C{1H} NMR 
(CDCl3, 75.5 MHz, 300.0 K) δ 187.9 (Q), 161.4 (Q), 138.9 (2 x 
Q), 132.5 (Q), 129.1 (2 x CH), 129.0 (2 x CH), 125.5 (CH), 124.7 
(2 x CH), 114.0 (2 x CH), 93.8 (methine CH), 63.6 (ethoxy 
CH2), 20.5 (aliphatic CH3), 14.8 (ethoxy CH3) Analysis 
Calculated for C18H19NO: C75.23, H 5.65, N 13.85 Analysis 
Found for C18H19NO: C 74.75, H 5.70, N 13.80 ES MS (+): m/z 
282.15 [MH+] 
 
Ligand L11 (0.42 g, 1.7 mmol, 59%) 
1H NMR (CDCl3, 500.13 MHz, 319.2 K) δ 13.12 (br. s, 1H, NH), 
7.87 (d, 2H, CH, 3J (1H-1H) = 8.2 Hz), 7.41 (d, 2H, CH, 3J (1H-
1H) = 7.6 Hz), 7.28 (m, 2H, CH), 7.25 (m, 2H, CH), 7.23 (m, 
1H, CH), 5.89 (s, 1H, methine CH), 2.44 (s, 3H, aliphatic 
CH3), 2.19 (s, 3H, methyl CH3) 13C{1H} NMR (CDCl3, 75.5 
MHz, 300.0 K) δ 189.0 (Q), 162.2 (Q), 141.7 (Q), 139.2 (Q), 
137.7 (Q), 129.7 (2 x CH), 129.4 (2 x CH), 127.5 (CH), 126.1 
(CH), 125.1 (2 x CH), 94.5 (methine CH), 21.9 (aliphatic CH3), 
20.9 (methyl CH3) Analysis Calculated for C17H17NO: C81.20, 
H 6.82, N 5.60% Analysis Found for C17H17NO: C 79.80, H 
6.80, N 5.10 ES MS (+): m/z 252.20 [MH+] 
 
Ligand 12 (0.65 g, 2.3 mmol, 81%) 
1H NMR (CDCl3, 500 MHz, 300.0 K) δ 13.13 (br. s, 1H, NH), 
8.51 (d, 2H, CH, 3J (1H-1H) = 8.3 Hz), 7.89 (br. t, 2H, CH, 3J 
(1H-1H) = 8.3 Hz), 7.70 (br. d, 1H, CH, 4J (1H-1H) = 6.9 Hz), 
7.57-7.53 (m, 1H, CH), 7.53-7.48 (m, 2H, CH), 7.42 (br, t, 2H, 
CH, 3J(1H-1H) = 8.3 Hz), 7.28-7.25 (m, 2H, CH), 5.70 (s, 1H, 
methine CH), 2.16 (s, 3H, aliphatic CH3) 
13C{1H} NMR (CDCl3, 
125 MHz, 300 K) δ 193.0 (Q), 162.0 (Q), 143.2 (Q), 140.1 (Q), 
138.6 (2 x Q), 130.3 (CH), 129.9 (CH), 129.2 (CH), 128.4 (CH), 
126.6 (CH), 126.1 (CH), 125.4 (CH), 124.9 (CH), 124.9 (CH), 
 99.0 (methine CH), 20.3 (aliphatic CH3) Analysis Calculated 
for C20H17NO: C 83.59, H 5.96, N 4.87% Analysis Found for 
C20H17NO: C 83.70, H 6.00, N 4.80% ES MS (+): m/z 288.14 
[MH+] 
 
Ligand L13 (0.56 g, 1.9 mmol, 64%) 
1H NMR (CDCl3, 300.13 MHz, 300.0 K) δ 12.90 (br. s, 1H, NH), 
7.97-7.92 (m, 2H, CH), 7.16-7.09 (m, 3H, 3 x CH), 6.99 (ddd, 
1H, CH, 3J (1H-1H) = 9.0 Hz and 3J (1H-19F) = 3.1 and 2.0 Hz), 
6.93–6.87 (m, 1H, CH), 5.95 (s, 1H, methine CH), 2.17 (s, 3H, 
aliphatic CH3) 
13C{1H} NMR (CDCl3, 125.9 MHz, 300.0 K) δ 188.1 (Q), 164.8 (d, Q, C-F, 1J (13C-19F) = 250.5 Hz), 161.5 (Q), 
158.3 (dd, Q C-F, 1J (13C-19F) = 242.3 Hz and 4J (13C-19F) = 3.1 
Hz), 152.7 (dd, Q C-F, 1J (13C-19F) = 242.3Hz and 4J (13C-19F) = 
3.1 Hz), 135.7 (d, Q, 4J(13C-19F) = 3.1 Hz), 129.6 (d, 2 x CH, 3J 
(13C-19F) = 8.3 Hz). 127.9 (dd, Q, 2J (13C-19F) = 24.7 Hz and 3J 
(13C-19F) = 4.1 Hz), 115.3 (d, 3 x CH, 3J (13C-19F) = 21.7 Hz), 113.1 
(d, CH, 3J(13C-19F) = 23.7 Hz), 113.0 (d, CH, 2J (13C-19F) = 
25.8Hz), 95.3 (methine CH), 20.3 (aliphatic CH3) Analysis 
Calculated for C16H12F3NO: C 65.98, H 4.15, N 4.81% Analysis 
Found for C16H12F3NO: C 65.35, H 4.35, N 4.70% ES MS (+): 
m/z 292.09 [MH+] 
 
Ligand L14 
This ligand was prepared as previously reported by 
Roshchupkina et al.18 
 
Complexes 2-13 
Complexes 2-13 were synthesised by addition of [p-
cymRuCl2]2 (1 eq), a functionalised β-ketoiminate ligand (2 
eq) and Et3N (2 eq). All were stirred in dichloromethane (30 
mL) at room temperature overnight. The solvent was 
removed under reduced pressure and the crude product 
recrystallised using slow evaporation from a methanolic 
solution. 
 
Complex 2 (0.07 g, 0.13 mmol, 54%) 
1H NMR (CDCl3, 500.57 MHz, 300.0 K) δ 7.84 (d, 2H, CH, 3J 
(1H-1H)= 9.0 Hz and 4J (1H-1H)= 2.2 Hz), 7.75 (br. d, 1H, CH, 3J 
(1H-1H)= 9.0 Hz), 7.43 (br. t, 2H, CH, 3J (1H-1H)= 7.7 Hz), 7.26-
7.22 (br. dd, 1H, CH, 3J (1H-1H)= 6.2 Hz and 4J (1H-1H) = 2.1 
Hz), 7.09 (br. d, 1H, CH, 3J (1H-1H)= 6.9 Hz), 7.03-6.99 (a. t (v. 
dd), 2H, CH, 3J (1H-1H) = 8.6 Hz and 4J (1H-1H) = 3.9 Hz), 5.37 
(s, 1H, methine CH), 5.35 (br. d, 1H, CH, 3J (1H-1H) = 6.0 Hz), 
5.16 (br. d, 1H, CH, 3J (1H-1H) = 6.0 Hz), 5.06 (br. d, 1H, CH, 3J 
(1H-1H) = 5.6 Hz), 3.68 (br. d, 1H, CH, 3J (1H-1H) = 5.6 Hz), 
2.67 (br. sept, 1H, CH(CH3)2, 
3
J (1H-1H) = 6.9 Hz), 2.03 (s, 3H, 
methyl CH3), 1.79 (s, 3H, aliphatic CH3), 1.20 (a. t (v.dd), 6H, 
CH(CH3)2, 
3
J (1H-1H) = 7.5 Hz) 13C{1H} NMR (CDCl3, 125.9 
MHz, 300.0 K) δ (170.6 (Q), 164.8 (Q), 163.6 (d, Q C-F, 1J (13C-
19F) = 247.4 Hz), 157.2 (Q), 137.5 (Q), 129.6 (2 x CH), 128.2 (d, 
2 x CH, 3J (13C-19F) = 7.3 Hz), 126.1 (CH), 125.4 (CH), 123.9 
(CH), 114.6 (d, 2 x CH, 2J (13C-19F) = 21.7 Hz), 100.8 (Q), 96.2 
(Q), 94.2 (methine CH), 87.0 (CH), 84.6 (CH), 84.5 (CH), 
79.4 (CH), 30.5 (CH(CH3)2), 24.7 (aliphatic CH3), 23.6 
(CH(CH3)2), 20.9 (CH(CH3)2), 18.3 (methyl CH3) Analysis 
Calculated for C26H27ClFNORu: C 59.48, H 5.18, N 2.67% 
Analysis Found for C26H27ClFNORu: C 59.25, H 5.20, N 2.75% 
ES MS (+): m/z 490.11 [M+]-Cl 
 
Complex 3 (0.06 g, 0.11 mmol, 62%) 
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ  7.81-7.77 (br. dt, 
CH, 3J (1H-1H) = 8.7 Hz and 4J (1H-1H)= 1.8 Hz ), 7.74 (br. d, 
1H, CH, 3J (1H-1H)= 7.5 Hz), 7.43 (br. t, 2H, CH, 3J (1H-1H)= 8.3 
Hz), 7.30 (br. dt, 2H, CH, 3J (1H-1H)= 8.7 Hz and 4J (1H-1H)= 
2.0 Hz), 7.26-7.22 (br. t, 1H, CH, 3J (1H-1H)= 7.5 Hz), 7.09 (br. 
d, 1H, CH, 3J (1H-1H) = 6.8 Hz), 5.39 (s, 1H, methine CH), 5.35 
(br. d, CH, 3J (1H-1H) = 6.0 Hz), 5.16 (br. d, 1H, CH, 3J (1H-1H) 
= 6.0 Hz), 5.06 (br. d, 1H, CH, 3J (1H-1H) = 5.6 Hz), 3.68 (br. d, 
1H, CH, 3J (1H-1H) = 5.6 Hz), 2.67 (br. sept, 1H, CH(CH3)2, 
3
J 
(1H-1H) = 7.0 Hz), 2.03 (s, 3H, methyl CH3), 1.79 (s, 3H, 
aliphatic CH3), 1.21 (d, 3H, CH(CH3)2, 
3
J (1H-1H) = 9.9 Hz), 1. 
91 (d, 3H, CH(CH3)2, 
3
J (1H-1H) = 9.9 Hz) 13C{1H} NMR (CDCl3, 
75.5 MHz, 300.1 K) δ 170.3(Q), 164.9 (Q), 157.2 (Q), 138.0 (Q), 
135.2 (Q), 129.6 (CH), 128.2 (CH), 128.0 (CH), 127.8 (CH), 126.0 
(CH), 125.5 (CH), 123.3 (CH), 104.4 (Q), 96.3 (Q), 94.5 
(methine CH), 87.1 (CH), 84.6 (CH), 84.7 (CH), 84.7 (CH), 
79.5 (CH), 30.5 (CH(CH3)2), 24.7 (aliphatic CH3), 23.6 
(CH(CH3)2), 20.9 (CH(CH3)2), 18.4 (methyl CH3) Analysis 
Calculated for C26H27Cl2NORu: C 57.67, H 5.03, N 2.59, Cl 
13.09% Analysis Found for C26H27Cl2NORu: C 57.40, H 5.00, 
N 2.40, Cl 13.05% ES MS (+): m/z 506.08 [M+]-Cl 
 
Complex 4 (0.06 g, 0.11 mmol, 62%) 
1H NMR (CDCl3, 500.13 MHz, 240.2 K) δ 7.72 (br. d, 1H, CH, 3J 
(1H-1H) = 7.8 Hz ), 7.45 (br. d, 2H, CH, 3J (1H-1H)= 6.2 Hz), 
7.35 (br. d, 1H, CH, 3J (1H-1H)= 5.9 Hz), 7.32 (br. d, 1H, CH, 3J 
(1H-1H) = 8.2 Hz), 7.26-7.23 (m, 1H, CH), 7.20 (br. dd, 1H, CH, 
3
J (1H-1H)= 8.2 Hz and 4J (1H-1H)= 1.9 Hz), 5.30 (br. d, 1H, CH), 
5.22 (br. d, 1H, CH, 3J (1H-1H) = 6.0 Hz), 5.01 (br. d, 1H, CH, 3J 
(1H-1H) = 5.2 Hz), 4.93 (s, 1H, methine CH), 3.44 (br. d, 1H, 
CH, 3J (1H-1H) = 5.1 Hz), 2.74 (br. sept, CH(CH3)2, 
3
J (1H-1H) = 
6.6 Hz), 2.05 (s, 3H, methyl CH3), 1.74 (s, 3H, aliphatic CH3), 
1.27 (br. d, 3H, CH(CH3)2, 
3
J (1H-1H) = 6.7 Hz), 1. 22 (br. d, 3H, 
CH(CH3)2, 
3
J (1H-1H) = 6.7 Hz) 13C{1H} NMR (CDCl3, 125.8 
MHz, 240.2 K) δ 171.5 (Q), 164.3 (Q), 156.7 (Q), 138.5 (Q), 133.9 
(Q C-Cl), 131.4 (Q C-Cl), 130.9 (CH), 129.6 (CH), 129.1 (CH), 
127.8 (CH), 126.7 (CH), 125.2 (CH), 99.6 (Q), 98.1 (methine 
CH), 97.2 (Q), 87.8 (CH), 83.4 (CH), 83.2 (CH), 79.9 (CH), 
30.1 (CH(CH3)2), 24.6 (aliphatic CH3), 23.8 (CH(CH3)2), 21.1 
(CH(CH3)2), 18.8 (methyl CH3) Analysis Calculated for 
C26H26Cl3NORu: C 54.22, H 4.55, N 2.43, Cl 18.47% Analysis 
Found for C26H26Cl3NORu: C 54.05, H 4.65, N 2.35, Cl 18.45% 
ES MS (+): m/z 540.04 [M+]-Cl 
 
Complex 5 (0.32 g, 0.56 mmol 61%) 
1H NMR (CDCl3, 300.13 MHz, 295.5 K) δ (7.78-7.73 (m, 1H, 
CH), 7.47-7.43 (br. d, 2H, CH), 7.42 (m, 1H, CH), 7.25 (d, 2H, 
CH, 3J (1H-1H)= 7.0 Hz), 7.21-7.16 (m, 1H, CH), 7.13-7.08 (m, 
1H, CH), 5.28 (br. d, 1H, CH, 3J (1H-1H) = 6.2 Hz), 5.14 (br. d, 
1H, CH, 3J (1H-1H) = 6.2 Hz), 5.02 (br. d, 1H, CH, 3J (1H-1H) = 
5.5 Hz), 4.94 (s, 1H, methane CH), 3.64 (br. d, 1H, CH, 3J (1H-
1H) = 5.7 Hz), 2.76 (br. sept, 1H, CH(CH3)2, 
3
J (1H-1H) = 7.0 
Hz), 2.07 (s, 3H, methyl CH3), 1.74 (s, 3H, aliphatic CH3), 1.28 
(br. d, 3H, CH(CH3)2, 
3
J (1H-1H) = 6.8 Hz), 1.22 (br. d, 3H, 
CH(CH3)2, 
3
J (1H-1H) = 7.0 Hz) 13C{1H} NMR (CDCl3, 75.5 
MHz, 295.6 K) δ 171.4 (Q), 164.9 (Q), 156.9 (Q, 2 x C-Cl), 141.7 
(Q), 132.3 (Q), 130.6 (CH), 130.2 (CH), 129.0 (CH), 127.0 (CH), 
125.8 (CH), 125.6 (CH), 123.2 (CH), 100.7 (Q), 98.5 (methine 
CH), 97.2 (Q), 87.0 (CH), 83.7 (CH), 83.5 (CH), 80.4 (CH), 
30.3 (CH(CH3)2), 24.3 (aliphatic CH3), 23.5 (CH(CH3)2), 21.4 
(CH(CH3)2), 18.6 (methyl CH3) Analysis Calculated for 
C26H26Cl3NORu: C 54.22, H 4.55, N 2.43, Cl 18.47% Analysis 
Found for C26H26Cl3NORu: C 53.95, H 4.50, N 2.35, Cl 18.70% 
ES MS (+): m/z 540.05 [M+]-Cl 
 
 Complex 6 (0.06g, 0.10 mmol, 60%) 
1H NMR (CDCl3, 300.13 MHz, 300.0 K) δ 7.75 (dd, 1H, CH, 3J 
(1H-1H)= 7.3 Hz, 4J (1H-1H)= 1.6 Hz), 7.45 (br. t, 2H, CH, 
3
J (1H-
1H)= 8.5 Hz), 7.34 (d, 1H, CH, 
3
J (1H-1H)= 8.3 Hz), 7.27-7.22 (m, 
2H, CH), 7.14-7.09 (m, 1H, CH), 5.27 (br. d, 1H, CH, 3J (1H-1H) 
= 6.2 Hz), 5.12 (br. d, 1H, CH, 3J (1H-1H) = 6.2 Hz), 5.03 (br. d, 
1H, CH, 3J (1H-1H) = 5.7 Hz), 4.88 (s, 1H, methine CH), 3.63 
(br. d, 1H, CH, 3J (1H-1H) = 5.7 Hz), 2.76 (br. sept, 1H, 
CH(CH3)2, 
3
J (1H-1H) = 7.0 Hz), 2.07 (s, 3H,methyl CH3), 1.74 
(s, 3H,aliphatic CH3), 1.30 (d, 3H, CH(CH3)2, 
3
J (1H-1H) = 6.8 
Hz), 1. 23 (d, 3H, CH(CH3)2, 
3
J (1H-1H) = 7.0 Hz) 13C{1H} NMR 
(CDCl3, 75.5 MHz, 295.6 K) δ 171.7 (Q), 165.0 (Q), 156.9 (Q), 
141.0 (Q), 133.4 (Q, C-Cl), 131.5 (Q, C-Cl), 130.9 (Q, C-Cl, C22-
24), 129.7 (2 x CH), 128.5 (CH), 128.1 (CH), 127.8 (CH), 125.6 
(CH), 123.2 (CH), 100.8 (Q), 98.5 (methine CH), 97.2 (Q), 87.0 
(CH), 83.8 (CH), 83.7 (CH), 80.4 (CH), 30.3 (CH(CH3)2), 24.3 
(aliphatic CH3), 23.6 (CH(CH3)2), 21.4 (CH(CH3)2), 18.6 
(methyl CH3) Analysis Calculated for C26H25Cl4NORu: C 51.16, 
H 4.13, N 2.29, Cl 23.23 % Analysis Found for C26H25Cl4NORu: 
C 51.00, H 4.15, N 2.20, Cl 23.20% ES MS (+): m/z 574.00 [M+]-
Cl 
 
Complex 7 (0.31 g, 0.54 mmol, 71%) 
1H NMR (CDCl3, 500.23 MHz, 300.0 K) δ 8.00 (br. t, 1H, CH, 4J 
(1H-1H) = 1.6 Hz), 7.76-7.73 (br. d, 2H, CH, 3J (1H-1H) = 8.0 
Hz), 7.48 (br. d, 1H, CH, 3J (1H-1H)= 7.6 Hz), 7.43 (br. t, 2H, 
CH, 3J (1H-1H)= 7.5 Hz), 7.24 (br. t, 1H, CH, 3J (1H-1H)= 7.6 
Hz), 7.20 (t, 1H, CH, 3J (1H-1H) = 7.9 Hz), 7.09 (d, 1H, CH, 3J 
(1H-1H) = 6.4 Hz), 5.38 (s, 1H, methine CH), 5.35 (br. d, 1H, 
CH, 3J (1H-1H) = 6.4 Hz), 5.17 (br. d, 1H, CH, 3J (1H-1H) = 6.0 
Hz), 5.07 (br. d, 1H, CH, 3J (1H-1H) = 5.6 Hz), 3.69 (br. d, 1H, 
CH, 3J (1H-1H) = 5.6 Hz), 2.67 (br. sept, 1H, CH(CH3)2), 2.03 (s, 
3H, methyl CH3), 1.79 (s, 3H, aliphatic CH), 1.22 (d, 3H, 
CH(CH3)2, 
3
J (1H-1H) = 7.1 Hz), 1.20 (d, 3H, CH(CH3)2, 
3
J (1H-
1H) = 7.1 Hz) 13C{1H} NMR (CDCl3, 125.9 MHz, 301.2 K) δ 169.9 
(Q), 165.1 (Q), 157.1 (Q, C-Br), 141.7 (Q), 132.1 (CH), 130.0 (2 x 
CH), 129.7 (CH), 129.3 (CH), 127.8 (CH), 125.4 (CH), 125.4 
(CH), 123.3 (CH), 122.2 (Q), 101.0 (Q), 94.8 (methine CH), 87.1 
(CH), 84.6 (CH), 84.4 (CH), 79.4 (CH), 30.5 (CH(CH3)2), 24.7 
(aliphatic CH3), 23.3 (CH(CH3)2), 21.0 (CH(CH3)2), 18.4 ( 
methyl CH3) Analysis Calculated for C26H27BrClNORu: C 
53.30, H 4.64, N 2.39% Analysis Found for C26H27BrClNORu: 
C 52.90, H 4.60, N 2.35% ES MS (+): m/z 522.03 [M+]-Cl (79Br) 
 
Complex 8 (0.19 g, 0.32 mmol, 66%) 
1H NMR (CDCl3, 300 MHz, 300 K) δ 7.76-7.70(m, 3H, 3 x CH), 
7.49-7.44 (m, 3H, 3 x CH), 7.42 (br. d, 1H, CH, 3J (1H-1H)= 7.6 
Hz), 7.23 (a. br. t, 1H, CH, 3J (1H-1H)= 7.4 Hz), 7.09 (br. d, 1H, 
CH, 3J (1H-1H)= 6.4 Hz), 5.39 (s, 1H, methine CH), 5.35 (br. d, 
1H, CH, 3J (1H-1H) = 6.2 Hz), 5.16 (br. d, 1H, CH, 3J (1H-1H) = 
6.2 Hz), 5.07 (br. d, 1H, CH, 3J (1H-1H) = 5.3 Hz), 3.68 (br. d, 
1H, CH, 3J (1H-1H) = 5.7 Hz), 2.66 (br. sept, 1H, CH(CH3)2, 
3
J 
(1H-1H) = 6.9 Hz), 2.02 (s, 3H, methyl CH3), 1.79 (s, 3H, 
aliphatic CH3), 1.20 (a. t, 6H, CH(CH3)2, 
3
J (1H-1H) = 6.3 Hz) 
13C{1H} NMR (CDCl3, 75 MHz, 300 K) δ 164.9 (Q), 157.2 (Q), 
138.7 (Q, C-Br), 135.2 (Q), 130.9 (2 x CH), 129.6 (CH), 128.5 (2 x 
CH), 127.8 (CH), 126.0 (CH), 125.5 (CH), 123.3 (CH), 100.9 (Q), 
96.2 (Q), 94.4 (methine CH), 87.1 (CH), 84.6 (CH), 84.5 (CH), 
79.4 (CH), 30.5 (CH(CH3)2), 24.7 (aliphatic CH3), 23.3 
(CH(CH3)2), 20.9 (CH(CH3)2), 18.4 (methyl CH3) Analysis 
Calculated for C26H27BrClNORu: C 53.30, H 4.64, N 2.39% 
Analysis Found for C26H27BrClNORu: C 53.20, H 4.65, N 
2.30% ES MS (+): m/z 552.03 [M+]-Cl (79Br) 
 
Complex 9 (0.16 g, 0.25 mmol, 62%) 
1H NMR (CDCl3, 300 MHz, 300 K) δ 7.74 (d, 2H, 2 x CH, 3J 
(1H-1H)= 8.3 Hz ), 7.49-7.44 (m, 3H, 3 x CH), 7.42 (br. d, 1H, 
CH, 3J (1H-1H)= 7.6 Hz), 7.23 (a. br. t, 1H, CH, 3J (1H-1H)= 7.4 
Hz), 7.09 (br. d, 1H, CH, 3J (1H-1H)= 6.4 Hz), 5.39 (s, 1H, 
methine CH), 5.35 (br. d, 1H, CH, 3J (1H-1H) = 6.2 Hz), 5.16 
(br. d, 1H, CH, 3J (1H-1H) = 6.2 Hz), 5.07 (br. d, 1H, CH, 3J (1H-
1H) = 5.3 Hz), 3.68 (br. d, 1H, CH, 3J (1H-1H) = 5.7 Hz), 2.66 
(br. sept, 1H, CH(CH3)2, 
3
J (1H-1H) = 6.9 Hz), 2.02 (s, 3H, 
methyl CH3), 1.79 (s, 3H, aliphatic CH3), 1.20 (a. t, 6H, 
CH(CH3)2, 
3
J (1H-1H) = 6.3 Hz) 13C{1H} NMR (CDCl3, 75 MHz, 
300 K) δ 165.0 (Q), 157.2 (Q), 137.0 (Q, C-I), 135.2 (Q), 130.9 (2 
x CH), 129.7 (CH), 128.7 (2 x CH), 127.8 (CH), 126.0 (CH), 125.5 
(CH), 123.3 (CH), 100.9 (Q), 95.7 (Q), 94.5 (methine CH), 87.1 
(CH), 84.7 (CH), 84.5 (CH), 79.5 (CH), 30.5 (CH(CH3)2), 24.7 
(aliphatic CH3), 23.4 (CH(CH3)2), 21.0 (CH(CH3)2), 18.4 
(methyl CH3) Analysis Calculated for C26H27ClINORu: C 
49.34, H 4.30, N 2.21% Analysis Found for C26H27ClINORu: C 
48.80, H 4.30, N 2.20% ES MS (+): m/z 632.85 [M+] 
 
Complex 10 (0.16 g, 0.29 mmol, 68%) 
1H NMR (CDCl3, 500.57 MHz, 300.7 K) δ 7.82 (br. d, 2H, CH, 
3
J (1H-1H)= 8.7 Hz), 7.76 (br. d, 1H, CH, 3J (1H-1H)= 8.2 Hz), 
7.42 (br. t, 2H, CH, 3J (1H-1H)= 7.6 Hz), 7.25-7.20 (m, 1H, CH), 
7.10 (br. d, 1H, CH, 3J (1H-1H)= 7.4 Hz), 6.84 (br. d, 2H, CH, 3J 
(1H-1H)= 8.7 Hz), 5.39 (s, 1H, methine CH), 5.34 (br. d, 1H, 
CH, 3J (1H-1H) = 5.0 Hz), 5.16 (br. d, 1H, CH, 3J (1H-1H) = 6.0 
Hz), 5.05 (br. d, 1H, CH, 3J (1H-1H) = 5.0 Hz), 4.07 (q, 2H, 
ethoxy CH2, 
3
J (1H-1H) = 6.9 Hz), 3.69 (br. d, 1H, CH, 3J (1H-
1H) = 5.0 Hz), 2.68 (br. sept, 1H, CH(CH3)2, 
3
J (1H-1H)= 7.4 
Hz), 2.03 (s, 3H, methyl CH3), 1.78 (s, 3H, aliphatic CH3), 1.43 
(t, 3H, ethoxy CH3, 
3
J (1H-1H) = 6.9 Hz), 1.24-1.16 (br. t, 6H, 
CH(CH3)2, 
3
J (1H-1H) = 6.9 Hz) 13C{1H} NMR (CDCl3, 125.5 
MHz, 300.7 K) δ 171.4 (Q), 164.3 (Q), 160.2 (Q), 157.4 (Q), 
131.(Q), 128.5 (2 x CH), 127.7 (2 x CH), 126.3 (CH), 125.3 (CH), 
123.7 (CH), 113.6 (2 x CH), 100.7 (Q), 96.1 (Q), 93.5 (methine 
CH), 87.1 (CH), 84.6 (CH), 84.4 (CH), 79.4 (CH), 63.4 (ethoxy 
CH2), 30.5 (CH(CH3)2), 24.7 (aliphatic CH3), 23.4 (CH(CH3)2), 
21.0 (CH(CH3)2), 18.4 (methyl CH3), 14.8 (ethoxy CH3) 
Analysis Calculated for C28H32ClNORu: C 61.03, H 5.85, N 
2.54, Cl 6.43% Analysis Found for C28H32ClNORu: C 59.65, H 
5.85, N 2.55, Cl I/m% ES MS (+): m/z 516.15 [M+]-Cl 
 
Complex 11 (0.06 g, 0.12 mmol, 62%) 
1H NMR (CDCl3, 300 MHz, 300 K) δ 7.76 (br. d, 2H, CH, 3J 
(1H-1H)= 8.3 Hz), 7.42 (br. t, 2H, CH, 3J (1H-1H)= 7.7 Hz), 7.25-
7.20 (m, 2H, CH), 7.14 (br. d, 2H, CH, 3J (1H-1H)= 7.9 Hz), 7.09 
(br. d, 1H, CH, 3J (1H-1H)= 7.2 Hz), 5.42 (s, 1H, methine CH), 
5.35 (br. d, 1H, CH, 3J (1H-1H) = 6.0 Hz), 5.17 (br. d, 1H, CH, 3J 
(1H-1H) = 6.0 Hz), 5.06 (br. d, 1H, CH, 3J (1H-1H) = 5.7 Hz), 
3.69 (br. d, 1H, CH, 3J (1H-1H) = 5.7 Hz), 2.68 (br. sept, 1H, 
CH(CH3)2, 3J (1H-1H)= 6.9 Hz), 2.37 (s, 3H, methyl CH3), 2.03 
(s, 3H, methyl CH3), 1.79 (s, 3H, aliphatic CH3), 1.24-1.16 (m, 
6H, CH(CH3)2) 
13C{1H} NMR (CDCl3, 75 MHz, 300 K) δ 171.7 
(Q), 164.5 (Q), 157.4 (Q), 139.4 (Q), 136.8.(Q), 128.5 (2 x CH), 
127.6 (2 x CH), 126.9 (CH), 125.3 (CH), 123.5 (CH), 100.7 (Q), 
96.2 (Q), 94.0 (methine CH), 87.2 (CH), 84.6 (CH), 84.4 
(CH), 79.4 (CH), 30.4 (CH(CH3)2), 24.7 (aliphatic CH3), 23.4 
(CH(CH3)2), 21.4 (methyl CH3), 20.9 (CH(CH3)2), 18.4 (methyl 
CH3) Analysis Calculated for C27H30ClNORu: C 62.24, H 5.80, 
N 2.69, Cl 6.80% Analysis Found for C27H30ClNORu: C 62.10, 
H 5.85, N 2.65, Cl 6.85% ES MS (+): m/z 486.14 [M+]-Cl 
  
Complex 12 (0.10 g, 0.17 mmol, 61%) 
1H NMR (CDCl3, 300 MHz, 300 K) δ 7.85-7.78 (m, 3H, 3 x 
CH), 7.53-7.36 (m, 9H, 9 x CH), 5.60 (s, 1H, methine CH), 
5.56 (br. d, 1H, CH, 3J (1H-1H) = 6.2 Hz), 5.49 (br. d, 1H, CH, 3J 
(1H-1H) = 5.5 Hz), 5.27 (br. d, 2H, CH, 3J (1H-1H) = 5.7 Hz), 
3.00-2.90 (br. q, 1H, CH(CH3)2), 2.13 (s, 3H, methyl CH3), 1.57 
(s, 3H, aliphatic CH3), 1.35 (dd, 6H, CHC(CH3)2, 
3J (1H-1H) = 
6.9 Hz and 3J (1H-1H) = 3.9Hz) 13C{1H} NMR (CDCl3, 75 MHz, 
300 K) δ 162.4 (Q), 154.3 (Q), 148.3 (Q), 133.7.(Q), 126.7 (Q), 
125.4 (Q), 129.8 (CH), 127.8 (CH), 126.4 (CH), 126.0 (CH), 
125.0 (CH), 124.6 (CH), 100.8 (Q), 99.8 (methine CH), 97.5 
(Q), 84.3 (CH), 82.5 (CH), 79.1 (CH), 79.0 (CH), 30.7 
(CH(CH), 27.9 (aliphatic CH3), 22.4 (CH(CH3)2), 22.3 
(CH(CH3)2), 17.9 (methyl CH3) Analysis Calculated for 
C30H30ClNORu: C 64.68, H 5.43, N 2.51, Cl 6.36% Analysis 
Found for C30H30ClNORu: C 61.70, H 5.35, N 1.55, Cl 7.30% ES 
MS (+): m/z 522.1 [M+]-Cl  
 
Complex 13 (0.18 g, 0.32 mmol, 62%) 
1H NMR (CDCl3, 300.13 MHz, 300.0 K) δ 7.88-7.81 (m, 2H, 
CH), 7.65 (ddd, 1H, CH, 3J (1H-19F)= 9.3 Hz, 4J (1H-19F)= 6.2 Hz 
and 4J (1H-1H)= 3.2 Hz), 7.18 (td, 1H, CH, 3J (1H-19F)= 9.1 Hz 
and 3J (1H-1H)= 4.8 Hz), 7.06-6.97 (m, 2H, CH), 6.93 (ddt, 1H, 
CH, 3J (1H-19F) = 9.1 Hz, 3J (1H-1H)= 7.2 Hz and 4J (1H-19F)= 3.5 
Hz), 5.43 (s, 1H, methine CH), 5.41 (br. d, 1H, CH, 3J (1H-1H) = 
5.7 Hz), 5.24 (br. d, 1H, CH, 3J (1H-1H) = 5.7 Hz), 5.18 (br. d, 
1H, CH, 3J (1H-1H) = 6.2 Hz), 3.86 (br. d, 1H, CH, 3J (1H-1H) = 
5.5 Hz), 2.65 (br. sept, 1H, CH(CH3)2, 
3
J (1H-1H)= 7.0 Hz), 2.05 
(s, 3H, methyl CH3), 1.82 (br. d, 3H, aliphatic CH3, 
5
J (1H-19F) 
= 0.8 Hz), 1.18 (dd (vt), 6H, CH(CH)3)2, 
3
J (1H-1H) = 7.3 Hz) 
13C{1H} NMR (CDCl3, 75.5 MHz, 300.1 K) δ 166.1 (Q), 163.8 (d, 
Q, C-F, 1J (13C-19F) = 247.2 Hz), 161.4 (Q), 155.0 (d, Q, C-F, 1J 
(13C-19F) = 213.9 Hz), 152.6 (d, Q, C-F, 1J (13C-19F) = 225.0 Hz), 
135.4 (Q), 131.3 (d, Q, 2J (13C-19F) = 119.9 Hz) 128.9 (2 x CH, 3J 
(13C-19F) = 8.7 Hz), 115.8 (d, CH, 2J (13C-19F) = 23.5 Hz), 115.6 (d, 
CH, 2J (13C-19F) = 23.5 Hz), 114.7 (2 x CH, 2J (13C-19F) = 22.3 Hz), 
113.3 (d, CH, 2J (13C-19F) = 16.1 Hz), 101.1 (Q), 96.1 (Q), 94.2 
(methine CH), 86.9 (CH), 84.9 (CH), 84.3 (CH), 78.5 (CH), 
30.6 (CH(CH3)2), 23.9 (CH(CH3)2), 23.2 (CH(CH3)2), 20.7 
(aliphatic CH3), 18.3 (methyl CH3) Analysis Calculated for 
C26H25ClF3NORu: C 55.66, H 4.49, N 2.50% Analysis Found 
for C26H25ClF3NORu: C 55.45, H 4.50, N 2.45% ES MS (+): m/z 
526.09 [M+]-Cl 
 
Complex14 (0.08 g, 0.21 mmol, 57%) 
Complex 14 was synthesised according to the previous 
ruthenium complex preparation, with addition of 2 
equivalents of diphenyl-β-ketoiminate ligand. 
1H NMR (CDCl3, 300 MHz, 300.0 K) δ 7.90-7.85 (m, 2H, CH), 
7.61-7.56 (m, 2H, CH), 7.45-7.30 (m, 2H, CH), 5.72 (d, 1H, NH, 
4
J (1H-1H) = 2.3 Hz), 5.45 (br. s, 2H, CH), 5.21 (m, 2H, CH), 
2.85 (br. sept, 1H, CH(CH3)2, 
3
J (1H-1H)= 7.0 Hz), 2.30 (s, 3H, 
methyl CH3), 1.32 (br. d, 6H, CH(CH3)2, 
3
J (1H-1H) = 6.8 Hz) 
13C{1H} NMR (CDCl3, 75 MHz, 300.0 K) δ 210.3 (Q), 206.4 (Q), 
174.5 (Q), 159.3 (Q), 129.7 (CH), 128.7 (CH), 127.8 (CH), 126.9 
(CH), 126.2 (CH), 100.9 (Q), 99.8 (Q), 99.3 (methine CH), 
91.8 (CH), 84.9 (CH), 30.7 (CH(CH3)2), 25.2 (2 x CH(CH3)2), 
18.3 (methyl CH3) Analysis Calculated for C20H24ClNORu: C 
60.91, H 5.32, N 2.84, Cl 7.19% Analysis Found for 
C20H24ClNORu: C 60.90, H 5.30, N 3.10, Cl 7.40% ES MS (+): 
m/z 456.33 [M+]-Cl 
 
Complex 17 (0.04 g, 0.06 mmol, 46%) 
Complex 17 was synthesised according to the previous 
ruthenium complex preparation, with addition of 2 
equivalents of NH-β-ketoiminate ligand. 
1H NMR (300 MHz, CDCl3, 300 K) δ 7.86-7.83 (m, 2H, CH), 
7.31 (ddd, 3H, CH, 3J (1H-1H) = 19.21 Hz, 11.5 Hz and 7.6 Hz,), 
5.38 (d, 1H, methine CH, 3J (1H-1H) = 2.1 Hz), 2.09 (s, 3H, 
aliphatic CH3), 1.68 (br. s, 15H, Cp * methyl CCH3) 
13C{1H} 
NMR (125 MHz, CDCl3, 300 K) δ 170.8 (Q), 163.1 (Q), 139.8 
(Q), 129.3 (CH), 128.0 (2 × CH), 126.7 (2 × CH), 94.0 (methine 
CH), 84.7 (Q, Cp* C(CH)3), 28.6 (aliphatic CH3), 8.7 (Cp * 
methyl, C(CH3)) Analysis Calculated for C20H25ClIrNO: C 
45.9, H 4.8, N 2.6 % Analysis Found for C20H25ClIrNO: C 45.9, 
H 4.8, N 2.6 %  
 
Complex 18 (0.07 g, 0.13 mmol, 58%) 
Complex 18 was synthesised by addition of [Cp*IrCl2]2 (1 eq), 
a 3-fluoro-β-diketonate ligand (2 eq) and Et3N (2 eq). All 
were stirred in dichloromethane (30 mL) at room 
temperature overnight. The solvent removed under reduced 
pressure and the crude product recrystallised using slow 
evaporation from a methanolic solution. 
1H NMR (CDCl3, 300 MHz, 299.2 K) δ 7.66-7.61 (m, 1H, CH), 
7.61-7.54 (m, 1H, CH), 7.35-7.28 (m, 1H, CH), 7.19-7.10 (m, 1H, 
CH), 5.85 (s, 1H, methine CH), 2.08 (s, 3H, CH3), 1.66 (br. s, 
15H, Cp* methyl C(CH)3) 
13C{1H} NMR (CDCl3, 75 MHz, 300 
K) δ 187.3 (Q), 175.5 (Q), 162.7 (d, Q, C-F, 1J (13C-19F) = 243.5 
Hz), 141.1 (Q), 129.6 (d, CH, 3J (13C-19F) = 8.7 Hz), 122.6 (d, CH, 
4J (13C-19F) = 2.5 Hz), 117.5 (d, CH, 2J (13C-19F) = 21.0 Hz), 113.9 
(d, CH, 2J (13C-19F) = 23.5 Hz), 97.3 (methine CH), 83.7 (Q, Cp* 
C(CH3)), 28.2 (aliphatic CH3), 8.7 (Cp* methyl C(CH3)) 
Analysis Calculated for C20H23ClFIrO2: C 44.31, H 4.28 % 
Analysis Found for C20H23ClFIrO2: C 44.55, H, 4.20,% ES MS 
(+): m/z 507.0 [MH+]-Cl. 
 
Cell Line Chemosensitivity Studies 
In vitro chemosensitivity tests were performed at the 
Institute of Cancer Therapeutics, Bradford, against MCF-7 
(human breast adenocarcinoma), HT-29 (human colon 
adenocarcinoma), A2780 (human ovarian carcinoma) and 
A2780cis (cisplatin resistant A2780 cells) cell lines. Growth 
inhibitory effects were also tested against ARPE-19 cells. 
ARPE-19 are a human retinal epithelial non-cancer cell line 
that was obtained from the American Type Culture 
Collection. Cancer cell lines were routinely maintained as 
monolayer cultures in appropriate medium (RPMI 1640 
supplemented with 10% foetal calf serum, sodium pyruvate (1 
mM) and L-glutamine (2 mM) AREP-19 cells were cultured in 
DMEM-F12 medium containing 10% foetal calf serum. For 
chemosensitivity studies, cells were incubated in 96-well 
plates at a concentration of 2 × 103 cells per well and the 
plates were incubated for 24 hours at 37 °C in an atmosphere 
of 5% CO2 prior to drug exposure. Complexes or cisplatin 
were each dissolved in dimethylsulfoxide to provide stock 
solutions that were diluted to provide a range of final 
concentrations. Drug solutions were added to cells (the final 
DMSO concentrations was less than 0.1% (v/v) in all cases) 
and incubated for 5 days at 37 °C in an atmosphere of 5% 
CO2. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) (20 µL, 5 mg mL−1) was added to each well 
and incubated for 3 hours at 37 °C in an atmosphere of 5% 
CO2. All solutions were then removed via pipette and 150 μL 
 of dimethylsulfoxide added to each well in order to dissolve 
the purple formazan crystals. A Thermo Scientific Multiskan 
EX microplate photometer was used to measure the 
absorbance of each well at 540 nm. Lanes containing 
medium only and 100% cells were used as blanks for the 
spectrophotometer and 100% cell survival respectively. Cell 
survival was determined as the absorbance of treated cells 
divided by the absorbance of controls and expressed as a 
percentage. The IC50 values were determined from plots of % 
survival against drug concentration. Each experiment was 
repeated three times and a mean value obtained and stated 
as IC50 (μM) ± SD. To quantify the response of tumour cells 
compared to normal cells, IC50 values were expressed as the 
ratio of IC50 in ARPE-19 cells divided by the IC50 for 
individual tumour cells evaluated. A ratio of greater than 1 
indicates selectivity towards cancer cells. IC50 values (µM) 
and the standard deviations (SD) after a minimum of three 
repeats are presented in Figure S2 (see SI) 
 
Influence of Hypoxia 
The hypoxia assay was conducted according to the protocol 
stated previously for normoxic conditions. However, the 
incubation period, the addition of the drug dilutions and the 
addition of the MTT solution were carried out inside a Don 
Whitley Scientific H35 Hypoxystation which was set at 1.0 
or 0.1% O2. Cisplatin was tested as a comparison and a well-
known hypoxic sensitive compound tirapazimine (TPZ) was 
tested as a positive control. These results are presented in 
Table S3a and S3b (see SI). 
 
Inhibition of thioredoxin reductase activity 
Thioredoxin reductase sourced from rat liver was obtained 
from Sigma Aldrich. It is a buffered aqueous glycerol 
solution, ≥ 100 units/ mg protein. Solution in 50 mM Tris-
HCl, pH 7.5, 300 mM NaCl, 1 mM EDTA, and 10% glycerol. 
The rate of change of UV-vis absorbance was measure at 412 
nm over 1 min to give the reaction velocity. The experiment 
was carried out using just the enzyme to get the control (no 
inhibitor) reaction velocity and then varying dilutions of the 
test compound were added up to a maximum of 10 µM. The 
reaction velocity in the presence of inhibitor was normalised 
relative to the control to generate % activity and plots of % 
activity versus concentration were constructed to obtain IC50 
values (concentration that inhibited 50% of enzyme activity) 
For full experimental and IC50 values cf. Figure S3 (see SI). 
 
Induction of Cancer Cell Death by Apoptosis 
Cells were incubated in T-25 flasks and diluted to 
concentrations of 2.5 x 104 cells/flask (0.5 x 104 cells/ mL) 
using complete RMPI 1640 medium. These were incubated 
for 24 hours at 37°C in an atmosphere of 5.0% CO2. 
Complexes were dissolved in dimethylsulfoxide and then 
further diluted with RMPI 1640 to obtained concentrations 
ranging from 20-0 µM. The cells were then incubated with 
the varying concentrations of complex for 48 hours, 
media/drug solutions were removed and flasks were washed 
with PBS (5 mL), adding all washings to a centrifuge tube. 
Trypsin (1 mL/flask) was added to each flask and then 
incubated for 5 minutes until a single cell suspension was 
obtained. The trypsin was then neutralised with medium (5 
mL) and the whole contents of the flask transferred to the 
same centrifuge tube. The tube was centrifuged at 1000 rcf 
for 3-5 minutes, the supernatant removed and the pellet re-
suspended in PBS (1 mL). The 1 mL was transferred to an 
Eppendorf and centrifuged at 1500 rpm for 5 minutes. The 
supernatant was removed and the pellet re-suspended in 16 µL PI, 16 µL AmV and 800 µL buffer solution (100 µL). The 
Eppendorf’s were incubated at room temperature for 10 
minutes and kept in suspension; and then transferred to 
FACS tubes for analysis. Samples were run using flow 
cytometry and parameters adjusted depending on the sample 
tested. A cell count of 10,000 was necessary to conduct this 
experiment and gave results of PI versus Annex V, each 
quadrant was analysed manually and a percentage taken 
from each quadrant of the plot, and values are presented in 
Table S8 (see SI). 
 
Analysis of cellular DNA damage by the comet assay 
Slides containing a layer of agarose were prepared in 
advance, using 1% normal melting point agarose (500 mg) in 
PBS (50 mL). The cells were diluted with complete RMPI 
1640 to a concentration of 1 x 106 cells/ mL, 2 mL of the cell 
suspension was placed in each well of a 6-well plate. The 
cells were incubated for 24 hours at 37˚C in a 5.0% CO2 
atmosphere. Drug samples were prepared in the range 20-0 µM, the medium was removed from the wells, and 2 mL of 
drug sample added to each well. The plate was then 
incubated again for 24 hours in the drug solutions, at 37˚C in 
a 5.0% CO2 atmosphere. The drug samples were removed 
and added to centrifuge tubes, the wells each washed with 
PBS (1 mL), which was also placed into the centrifuge tube. 
The wells were then trypsinised (1 mL) for 5 minutes and 
then neutralised with complete medium (1 mL), these were 
all added to the centrifuge tube and centrifuged at 1500 rpm 
for 3 minutes. The supernatant was removed and the pellet 
re-suspended in complete medium containing 10% DMSO 
(no not use DMSO with single strand assay). The tubes were 
wrapped in several sheets of tissue and stored at -80˚C until 
required for the assay. When conducting the cross-linking 
assay, the same protocol is followed with an additional step 
of exposing the cells to 10% H2O2 for 20 minutes before 
harvesting the cells. For reagents, conditions and graphically 
analysis see Figure S4-6 (SI) 
 
Supporting Information: Crystallographic data and select-
ed bond lengths and angles for ligands L3-6, 8 and 11, and 
complexes 2, 4-14, 17 and 18. Additional assays on hydropho-
bicity and hydrolysis. IC50 figures and tables for normoxic 
(HT-29, MCF-7, A2780, A2780cis and ARPE-19) and hypoxic 
assays (HT-29). Chemicals, experimental and data curves for 
thioredoxin reductase assay. Cell viability (%) for apoptosis 
studies (HT-29 and A2780), chemicals and experimental. 
Comet assay chemicals, experimental and bar-charts, with 
selected microscope images. This material is available free of 
charge via the Internet at http://pubs.acs.org.  
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